MOUNJARO

Eli Lilly awaits India's approval to sell Tirzepatide, marketed as Mounjaro and Zepbound in the US. CEO David Ricks plans to launch the drug in India in 2025, pending supply. The SEC recommends approval for pre-filled pens and vials, contingent on a...

People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage...

A new analysis highlights the significant cardiovascular benefits of Novo Nordisk's obesity drug Wegovy, showing improvements regardless of weight loss amount. This challenges perceptions of GLP-1 drugs, suggesting they could be viewed more as heart...

Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 6%.

Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife fo...

Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess its safety and efficacy compared to insulin glargine in individuals with Type 2 diabetes and obesity or overwe...

Eli Lilly plans to launch its diabetes and obesity drug, Mounjaro, in India next year. The drug contains tirzepatide and is sold as Zepbound in the US. The global market for GLP-1 receptor agonists, including Mounjaro, Wegovy, and Ozempic, is expect...

US drug maker Eli Lilly plans to launch its weight-loss drugs Zepbound and Mounjaro in India next year. The company is considering pricing based on supply and volume expansion. Eli Lilly CEO David Ricks suggests focusing on digital services in the I...

Indian drugmakers are developing their versions of Novo Nordisk's weight-loss treatment, Wegovy, aiming to capitalize on the growing weight-loss market, expected to reach $100 billion a year by the end of the decade. Companies like Sun Pharma, Cipla...

Shares were off about 1% at $696.82 after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capitalization and most valuable healthcare company.

With around half of the S&P 500 companies having reported earnings, 80.4% have surpassed expectations, according to LSEG data last week. Overall S&P 500 earnings are now expected to have risen 7.8% in the fourth quarter from the year-ago quarter.

In recent years, Ozempic, the winning diabetic drug is very much in demand, taking the world of weight loss by storm. Here's everything to know more

New data suggests that semaglutide may also cut the risk of stroke or heart attack, and may delay the progression of kidney disease in diabetes patients.

The increasing demand for weight-loss drugs such as Novo Nordisk's Ozempic has led to a rise in counterfeit versions of these medications. Law enforcement agencies, anti-counterfeiting organizations, and public health officials are collaborating to ...

U.S. companies in various sectors, including food and beverage, medical devices, and dialysis services, are facing questions from investors regarding the impact of weight-loss drugs on their future sales. Companies like Conagra and Walmart are consi...

Nestlé, the global food leader, is responding to the growing trend of appetite-suppressing weight-loss medications like Ozempic, Wegovy, and Mounjaro by innovating complementary products. These pharmaceutical advancements have prompted consideration...

According to doctors and fitness experts, queries come in every other day from (well-heeled) patients, asking whether they can take the expensive, injectable drugs to shed those stubborn kilos. “It’s coming up in conversations everywhere. Patients a...

A new study shows that the diabetes drug Mounjaro, when combined with intensive diet and exercise, helped people with obesity or who are overweight lose at least a quarter of their body weight, or about 60 pounds on average.

Mounjaro is making headlines recently. This antidiabetic injectable drug has been touted as the most powerful weight-loss drug available. In this article, we will explore what Mounjaro is, how it works, and the potential benefits and risks associate...